stockrow
Saturday 7 November 2026
Export CLOV’s income statement to Excel — free account
Clover Health Investments, Corp.
CLOV Healthcare Healthcare Plans
Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024.
- Revenue
- +52.9%
- EPS
- +350.0%
- Free cash flow
- +508.9%
Quarter to September 2026, against a year earlier
4.82
0.34
+7.59%
Follow CLOV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.63 | 0.42 | 1.11 | 0.84 | |
P/FCF ratio |
0.00 | 16.85 | 37.01 | 17.32 | |
P/Operating CF |
(17.65) | 8.52 | 109.05 | 32.56 | |
P/B ratio |
3.90 | 2.71 | 7.30 | 5.86 | |
Price to Tangible BV |
3.94 | 2.73 | 7.36 | 5.91 | |
EV/Sales |
0.57 | 0.33 | 1.02 | 0.76 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 162.36 | |
EV/Operating CF |
(16.50) | 12.87 | 32.78 | 15.30 | |
EV/FCF |
(16.01) | 13.51 | 34.03 | 15.65 | |
Quick Ratio |
1.03 | 0.82 | 0.98 | 0.28 | |
Current Ratio |
1.47 | 1.33 | 1.50 | 1.55 | |
Net Debt/EBITDA |
2.43 | (7.43) | (8.64) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.43 | 3.45 | 3.82 | 4.17 | |
Operating CF/Net income |
1.38 | 3.95 | 0.90 | 10.94 | |
Capex/Depreciation |
7.37 | (11.54) | (5.01) | (5.38) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
25.24% | 17.58% | 16.74% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.11% | 1.64% | 1.22% | 1.06% | |
Graham Net Nets |
0.06 | 0.10 | 0.05 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.34%) | (6.82%) | (0.95%) | (1.16%) | |
Free Cash Flow Yield |
(5.73%) | 5.93% | 2.70% | 5.77% | |
Revenue per Share |
0.95 | 1.43 | 1.42 | 1.43 | |
Operating CF per Share |
(0.13) | 0.21 | 0.05 | 0.13 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | 0.21 | 0.05 | 0.13 | |
Cash per Share |
0.23 | 0.39 | 0.46 | 0.00 | |
Shareholders Equity per Share |
0.60 | 0.65 | 0.72 | 0.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.60 | 0.65 | 0.72 | 0.74 | |
Free Cash Flow |
(68.75) | 107.04 | 24.51 | 69.48 | |
Working Capital |
99.03 | 111.44 | 162.12 | 189.16 | |
Capital Expenditures |
(0.60) | (0.85) | (0.68) | (0.90) | |
Net Current Asset Value |
75.55 | 89.72 | 141.38 | 172.25 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 166.22 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 184.02 | |
| Other line items | |||||
Average Receivables |
73.20 | 63.50 | 60.01 | 76.53 | |
Average Payables |
35.39 | 34.86 | 34.68 | 33.38 | |
Average Assets |
560.88 | 640.72 | 647.66 | 656.67 | |
Average Common Equity |
324.92 | 337.75 | 360.22 | 365.90 |
Columns are period end dates · fundamentals updated 6 Nov 2026